THC-Based Alzheimer's Trial In Puerto Rico: IGC Pharma Targets Underrepresented Hispanic Communities
Portfolio Pulse from Nicolás Jose Rodriguez
IGC Pharma, Inc. (IGC) has expanded its Phase 2 clinical trial for IGC-AD1, a THC-based investigational drug for Alzheimer's disease, to the University of Puerto Rico network. The expansion aims to increase population diversity and representation of underrepresented groups. The trial will enroll 146 patients, half of whom will receive IGC-AD1 and the other half a placebo. The goal is to evaluate the drug's efficacy in reducing agitation, a symptom affecting 76% of Alzheimer's patients.
August 04, 2023 | 12:21 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
IGC Pharma is expanding its Phase 2 clinical trial for its THC-based Alzheimer's drug, IGC-AD1, to Puerto Rico. This could potentially increase the diversity of the trial and the representation of underrepresented groups.
The expansion of the trial to Puerto Rico could potentially increase the diversity of the trial and the representation of underrepresented groups, which could enhance the validity of the trial results and potentially increase the market for the drug if it is approved.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEUTRAL IMPACT
The article mentions the Amplify Seymour Cannabis ETF (CNBS) in the context of cannabis-related ETFs.
The mention of CNBS in the article is not directly related to the news about IGC Pharma's trial, so it is unlikely to have a significant impact on the ETF.
CONFIDENCE 80
IMPORTANCE 20
RELEVANCE 20
NEUTRAL IMPACT
The article mentions the ETFMG Alternative Harvest (MJ) in the context of cannabis-related ETFs.
The mention of MJ in the article is not directly related to the news about IGC Pharma's trial, so it is unlikely to have a significant impact on the ETF.
CONFIDENCE 80
IMPORTANCE 20
RELEVANCE 20
NEUTRAL IMPACT
The article mentions the Global X Cannabis ETF (POTX) in the context of cannabis-related ETFs.
The mention of POTX in the article is not directly related to the news about IGC Pharma's trial, so it is unlikely to have a significant impact on the ETF.
CONFIDENCE 80
IMPORTANCE 20
RELEVANCE 20
NEUTRAL IMPACT
The article mentions the AXS Cannabis ETF (THCX) in the context of cannabis-related ETFs.
The mention of THCX in the article is not directly related to the news about IGC Pharma's trial, so it is unlikely to have a significant impact on the ETF.
CONFIDENCE 80
IMPORTANCE 20
RELEVANCE 20
NEUTRAL IMPACT
The article mentions the Cambria Cannabis ETF (TOKE) in the context of cannabis-related ETFs.
The mention of TOKE in the article is not directly related to the news about IGC Pharma's trial, so it is unlikely to have a significant impact on the ETF.
CONFIDENCE 80
IMPORTANCE 20
RELEVANCE 20
NEUTRAL IMPACT
The article mentions the AdvisorShares Pure Cannabis ETF (YOLO) in the context of cannabis-related ETFs.
The mention of YOLO in the article is not directly related to the news about IGC Pharma's trial, so it is unlikely to have a significant impact on the ETF.
CONFIDENCE 80
IMPORTANCE 20
RELEVANCE 20